A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice.
- DOI
- 10.1124/jpet.112.193946
- Published
- 2012 Jul 3
- Container
- The Journal of pharmacology and experimental therapeutics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1124/jpet.112.193946,
title = {A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice.},
author = {Sugiura T and Kageyama S and Andou A and Miyazawa T and Ejima C and Nakayama A and Dohi T and Eda H},
year = {2012},
journal = {The Journal of pharmacology and experimental therapeutics},
doi = {10.1124/jpet.112.193946},
url = {https://doi.org/10.1124/jpet.112.193946}
}RIS
TY - JOUR TI - A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice. AU - Sugiura T AU - Kageyama S AU - Andou A AU - Miyazawa T AU - Ejima C AU - Nakayama A AU - Dohi T AU - Eda H PY - 2012 JO - The Journal of pharmacology and experimental therapeutics DO - 10.1124/jpet.112.193946 UR - https://doi.org/10.1124/jpet.112.193946 ER -
APA
T, S., S, K., A, A., T, M., C, E., A, N., T, D., & H, E. (2012). A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice.. The Journal of pharmacology and experimental therapeutics. https://doi.org/10.1124/jpet.112.193946
Source records
- pubmed · retrieved 2026-09-25T09:09:02.380Z